IMUGENE
Developing Cancer Immunotherapies

ASX Announcement

Results of Meeting and Final Share Purchase Plan Allotment

Sydney, Australia, 23 April 2026:

Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to announce the results of today's Extraordinary General Meeting. The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporation's Act. All resolutions were passed and decided by way of a poll.

Imugene is also pleased to announce completion of the Share Purchase Plan, which was announced by the Company on 11 March 2026 (**SPP**) and closed on Monday, 20 April 2026.

The SPP follows on from the successful completion of tranche one of the institutional placement on 11 March 2026, following the Company securing firm commitments for $12 million at an issue price of $0.18 per share as part of a two-tranche placement. New Shares subscribed for under tranche two of the Institutional Placement were subject to Shareholder Approval, which was received at the Company's EGM on 23 April 2026.

The SPP raised a total of $2.18 million from the issue of 15,077,309 fully paid ordinary shares (**New Shares**) at an offer price of $0.145 per share, representing a 2.5% discount to the VWAP of shares traded on the ASX during the five trading days up to the closing date of the SPP, rounded to the nearest half cent. In addition, notices were received from institutional investors to subscribe for a shortfall of a further $1.82 million of applications under the SPP, bringing total proceeds raised under the Institutional Placement and SPP to $16 million.

New Shares subscribed for under the SPP (and the Attaching Options and Piggyback Options) were subject to Shareholder Approval, which was received at the Company's EGM today.

New Shares subscribed for under the SPP (and Attaching Options) will be issued on 24 April 2026.

E&P Capital Pty Ltd, Barrenjoey Markets Pty Ltd and Bell Potter Securities Ltd acted as Joint Lead Managers.

Imugene's CEO and Managing Director Leslie Chong said: "We thank those investors who participated in the share purchase plan for their continued support of the Company. This capital positions us well for the milestones ahead. The azer-cel data continues to strengthen, and with our oral presentation at ASCO in June, we look forward to sharing that progress with a global audience."

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

General Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Follow us on Twitter @TeamImugene
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)
Imugene is a clinical stage cell therapy company developing an allo CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.

Disclosure of Proxy Votes

Imugene Limited

Extraordinary General Meeting

Thursday, 23 April 2026

AUTOMIC
Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Ratification of prior issue of First Tranche Placement Shares to Placement Subscribers	P	49,953,523	47,506,849 95.10%	2,128,910 4.26%	9,008,171	317,764 0.64%	48,452,766 95.79%	2,131,263 4.21%	9,008,171	Carried
2 Ratification of prior issue of Subscription Shares to Precision Biosciences, Inc.	P	39,327,179	37,187,388 94.56%	1,849,395 4.70%	336,381	290,396 0.74%	38,108,290 95.37%	1,849,395 4.63%	336,381	Carried
3 Ratification of prior issue of New Convertible Notes to CVI Investments, Inc.	P	58,632,738	56,458,326 96.29%	1,912,434 3.26%	328,958	261,978 0.45%	57,350,810 96.77%	1,912,434 3.23%	328,958	Carried
4 Ratification of prior issue of New Subscription Warrants to CVI Investments, Inc.	P	58,634,351	56,510,059 96.38%	1,862,314 3.18%	327,346	261,978 0.45%	57,402,543 96.86%	1,862,314 3.14%	327,346	Carried
5 Approval to issue Second Tranche Placement Shares to Placement Subscribers	P	49,974,516	47,063,051 94.17%	2,593,771 5.19%	8,987,171	317,694 0.64%	48,008,898 94.87%	2,596,124 5.13%	8,987,171	Carried
6 Approval to issue Placement Attaching Options under the Placement Offer	P	49,968,563	47,070,620 94.20%	2,598,189 5.20%	8,993,136	299,754 0.60%	47,998,527 94.86%	2,600,542 5.14%	8,993,136	Carried
7 Approval to issue New Shares and SPP Attaching Options under the SPP Offer	P	49,991,497	47,102,874 94.22%	2,570,021 5.14%	8,970,203	318,602 0.64%	48,049,629 94.92%	2,572,374 5.08%	8,970,203	Carried
8 Approval to issue SPP Shortfall Commitment Options	P	49,942,146	47,087,706 94.28%	2,574,522 5.16%	9,019,555	279,918 0.56%	47,995,777 94.90%	2,576,875 5.10%	9,019,555	Carried

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**Total Number of Proxy Votes exercisable by proxies validly appointed**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
9 Approval to issue SAR Notes and New Warrants to the Noteholder in connection with the Convertible Note Raising	P	58,657,260	56,041,354 95.54%	2,353,928 4.01%	304,442	261,978 0.45%	56,931,485 96.03%	2,356,281 3.97%	304,442	Carried